sunbet

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
ת»ùÒòСÊó°¬×̲¡¶¯ÎïÄ£×Ó
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > ÄÚÉøÍ¸¼°´úлÐÔ¼²²¡Ä£×Ó > ת»ùÒòСÊó°¬×̲¡¶¯ÎïÄ£×Ó

ǰÑÔ

°¬×̲¡(acquired immunodeficiency syndrome,AIDS)ÔÚ1981ÄêÊ״η¢Ã÷ÓÚÃÀ¹ú £¬ËæºóÈ·¶¨Æä²¡Ô­ÌåΪÈËÀàÃâÒßȱÏݲ¡¶¾(human immunodeficiency virus,HIV),HIVÕ¹ÓÚ·´×ªÂ¼²¡¶¾Êô³ÉÔ± £¬ÊÇÒ»ÖÖѬȾÈËÀàÃâÒßϵͳϸ°ûµÄÂý²¡¶¾¡£²¡¶¾»ùÒò×éÓÉÁ½ÌõÏàͬµÄÕýÁ´RNA×é³É £¬È«³¤9.8kb £¬»®·Ö±àÂëGag¡¢Pol,Env½á¹¹ÂѰ׼°Tat¡¢Rev¡¢Vpu¡¢Vpr¡¢Vif¡¢NefµÈ¸¨ÖúÂѰס£HIVÓÐÁ½ÖÖѪÇåÐÍ £¬»®·ÖÊÇHIV-1ºÍHTV-2 £¬×î³£¼ûµÄΪHIV-1ѬȾ¡£HIVÈö²¥Í¾¾¶Ö÷Òª°üÀ¨ÐÔÈö²¥¡¢ÑªÒºÈö²¥ºÍĸӤÈö²¥µÈ;¾¶¾ÙÐÐÈö²¥ £¬Ñ¬È¾ºóÖ÷ÒªÇÖÕ¼ÃâÒßϸ°û £¬°üÀ¨Tϸ°û¡¢µ¥ºË¾ÞÊÉϸ°û¡¢Ê÷ͻ״ϸ°ûµÈ¡£Ï¸°ûÍâò±í´ïµÄCD4·Ö×ÓÊÇHIVÊÜÌå £¬HIVÄÒĤÌÇÂѰ×gp120Óëϸ°ûĤÉÏCD4·Ö×ÓÍŽáºó¿Éµ¼ÖÂѬȾµÄ±¬·¢ £¬AIDS»¼ÕßÁÙ´²ÌåÏÖÒÔCD4+TÁܰÍϸ°û¾ÙÐÐÐÔïÔÌ­ºÍÃâÒßȱÏÝÎªÌØÕ÷ £¬³£°éÓÐʵÖÊÆ÷¹Ù£¨ÄÔ¡¢ÁÜͶºÏºÍ·ÎµÈ£©µÄÑ×ÐÔ¼²²¡¡¢Éñ¾­Õϰ­ºÍ¶ñÐÔÖ×Áö¡£×ÔHIV±»·¢Ã÷ÒÔÀ´ £¬¿ÆÑ§¼ÒÃǼ´×îÏÈAIDS¶¯ÎïÄ£×ÓµÄÑо¿ÊÂÇé £¬Ð¡Êó¡¢Íü°·ÇÈËÁ鳤ÀදÎï¶¼ÔøÓÃÓÚAIDS¶¯ÎïÄ£×ÓµÄÑо¿¡£Æ¾Ö¤¶¯Îï¶ÔHIVµÄÃô¸ÐÐÔ¼°ÔìÄ£ÒªÁì £¬AIDS¶¯ÎïÄ£×Ó·ÖΪ·ÇÈËÁ鳤ÀදÎïÄ£×Ó¡¢×ª»ùÒòСÊóÄ£×Ó¼°ÈËÔ´»¯Ð¡ÊóÄ£×Ó¡£

·ÇÈËÁ鳤ÀදÎïÓÉÓÚËÇÑø±¾Ç®¸ß £¬ÇÒÐèÒªÌØÊâµÄËÇÑøÇéÐÎ £¬¸üÖ÷ÒªµÄÊÇÏÖÔÚÕë¶ÔÁ鳤ÀදÎïµÄÊÔ¼ÁºÜÉÙ £¬ÕâЩÒòËØ¶¼ÏÞÖÆÁËÆäÔÚ¶¯ÎïÄ£×ÓÑо¿ÖеÄÓ¦Óá£Ïà½ÏÁ¿¶øÑÔ £¬Äö³ÝÀදÎïÌåÐÍС¡¢Ò×ÓÚËÇÑø¡¢ÊÔ¼ÁȪԴÀû±ãµÈÒòËØ¾öÒéÁËÆäÔÚ¶¯ÎïÄ£×ÓÑо¿ÖÐÓÐÆæÒìµÄÓÅÊÆ¡£

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯ÎСÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

СÊó¶ÔHIV-1²¡¶¾²»Ò׸Р£¬HIV-1²¡¶¾²»¿ÉÔÚÆäÌåÄÚÔöÖ³¡£±¬·¢ÕâÖÖÕ÷ÏóµÄÔµ¹ÊÔ­ÓÉÒ»ÊÇСÊóºÍÈ˵ÄCD4·Ö×ÓÐòÁÐÓвî±ð £¬µ¼ÖÂHIV-1ÄÒĤÂѰײ»¿ÉÍŽᵽÊóCD4+Tϸ°û¡£Ò²ÓÐÑо¿·¢Ã÷HIV-1²¡¶¾ÐòÁÐÖг¤×îºóÖØ¸´ÐòÁÐ(long terminal repeat,LTR)½éµ¼µÄת¼»îÐÔÔÚÊóÔ´ÐÔϸ°û»îÐÔ½ÏµÍ £¬ÕâÒ²Êǵ¼ÖÂHIV-1²¡¶¾²»¿ÉѬȾСÊóµÄÔµ¹ÊÔ­ÓÉÖ®Ò»¡£±ðµÄ £¬HIV-1²¡¶¾µÄһЩ¸¨Öúµ÷¿ØÂÑ°× £¬Èç £¬ºËÊä³öÐźŷÖ×ÓRevÔÚÊóÔ´ÐÔϸ°ûÖеĹ¦Ð§Ï½µÏÔ×Å £¬²»¿ÉÓÐÓý鵼HIV-1mRNA³öºË £¬´Ó¶øÓ°Ï첡¶¾ÂѰ׷­ÒëºÍ°ü×°¡£Ëæ×Åת»ùÒòÊÖÒÕµÄÉú³¤ £¬½«HlV-1²¡¶¾ÊÜÌåCD4¼°Æä¸¨ÖúÊÜÌåCCR5ºÍCXCR4»ùÒòÈںϺóÏÔ΢עÉ䵽СÊóÊܾ«ÂÑϸ°û £¬ ¿ÉÖÆ±¸±í´ïÈËCD4-CCR5/CXCR4ת»ùÒòСÊó £¬¸ÃСÊóÓÉÓÚ±í´ïHIV-1²¡¶¾ÊÜÌå¼°¸¨ÖúÊÜÌå £¬Òò¶ø¶ÔHIV-1²¡¶¾µÄÒ׸ÐÐÔÌá¸ß £¬Ñ¬È¾ºó¿ÉÌåÏÖ³öAIDS²¿·ÖÖ¢×´¡£½«HIV-1²¡¶¾È«ÐòÁлò½á¹¹»ùÒò/µ÷¿Ø»ùÒò¿Ë¡ºóͨ¹ýÏÔ΢עÉäÒªÁìÒ²¿É½¨Éè±í´ïHIV-1ÌØÒìÂѰ׵Äת»ùÒòСÊó¡£

¡¾ÔìÄ£ÒªÁì¡¿£º

ͨ¹ýÏÔ΢עÉäÒªÁ콨ÉèµÄ±í´ïHIV-1²¡¶¾È«ÐòÁлò½á¹¹»ùÒò£¯µ÷¿Ø»ùÒòµÄת»ùÒòСÊó¿ÉÖ±½ÓÓÃÓÚ¿¹HIVÒ©Îïɸѡ¡¢ÒßÃçÆÀ¼ÛµÈÏà¹ØÑо¿ÁìÓò¡£300 TCID50µÄHIV-1²¡¶¾Æ¢ÄÚ½ÓÖÖ»ò8000TCID50HIV-1²¡¶¾¾²Âö½ÓÖÖCD4-CCR5ת»ùÒòСÊó £¬2~4Öܺó¶¯ÎïÔàÆ÷Öпɼì²âµ½HIV-1²¡¶¾DNA¡£

¡¾Ä£×ÓÌØµã¡¿£º

1.±í´ïHIV-1²¡¶¾ÐòÁÐת»ùÒòСÊó HIV-1ǰ²¡¶¾DNAÐòÁÐÏÔ΢עÉäµ½Êܾ«ÂÑϸ°ûºóÖÆ±¸³ö¿ÉÓÃÓÚAIDSÑо¿µÄת»ùÒòСÊó £¬×Ó´ú¶¯ÎïÖÐ50%~80£¥ÌåÏÖΪ±íƤÔöÉú¡¢ÁܰÍÑ×Ö¢¡¢Æ¢´ó¼°·ÎÁܰÍϸ°û½þÈóµÈ²¡ÀíÌåÏÖ £¬Æ¤·ô¡¢Æ¢Ô༰ÁÜͶºÏÖпɼì²âµ½HIV²¡¶¾¿ÅÁ£¡£Ò²ÓÐÑо¿ÕßÓÃȱʧGag-Pol»ùÒòµÄHIV-1²¡¶¾»ùÒòÐòÁÐÖÆ±¸AIDSת»ùÒòСÊóÄ£×Ó £¬¸ÃСÊóÉöÔàÖпɼì²âµ½HIV-1µÄÌØÒìÐÔ±í´ï £¬ºóÆÚСÊó¿ÉÉú³¤ÎªÓÐÂѰ×ÄòÖ¢×´µÄÉö²¡ÌåÏÖ £¬ÖÂËÀÂÊ½Ï¸ß £¬Òò´Ë¸ÃСÊóÓÃÓÚHIV-1ÒýÆðµÄÉö²¡Ä£×ÓÑо¿¡£±í´ï¸´ÖÆÈ±ÏÝÐÔHIV-1µÄת»ùÒòСÊóÒ²¿ÉÉú³¤ÓоÙÐÐÐÔÉöСÇòÓ²»¯ÎªÌåÏÖµÄÑÏÖØÉö²¡×ÛºÏÕ÷¡£±í´ïRevÂѰ׵Äת»ùÒòСÊóÉöСÇòÓ²»¯ £¬±íƤÔöÉú £¬Ð¡Ê󯤷ô×éÖ¯ÖÐÒ²¿É¼ì²âµ½²¡¶¾RNA¡£ÕâЩģ×ÓÊÇÑо¿HIVÏà¹ØÉö²¡µÄÓÅÒìÄ£×Ó¡£Ñо¿·¢Ã÷ÓÃMMTVÆô¶¯×ÓÈ¡´úHIVÆô¶¯×Óºó £¬EnvÂѰ׵Ägp160¡¢gp120ºÍGagÂѰ׵Äp55¡¢p24ÔÚת»ùÒòСÊóÌåÄÚ±í´ïÉϵ÷ £¬¸ÃÕ÷ÏóÓÈÆäÔÚ²¸ÈéÆÚ´ÆÐÔСÊóÖÐÌåÏÖÓÈÉõ¡£

2.HIV-1 LTRת»ùÒòСÊó »úÌåѬȾHIV-1ºóÓнϳ¤µÄDZÔÚÆÚ £¬ÁÙ´²Ö¢×´·ºÆð½ÏÍí £¬ÕâÓ벡¶¾×ªÂ¼»îÐÔÇ×½üÏà¹Ø¡£Ñо¿·¢Ã÷һЩÍâ½çÒòËØ£¨Èçϸ°ûÒò×Ó¡¢×ÏÍâÏߵȣ©¼°¾ßÓÐת¼»îÐԵĵ÷¿ØÔª¼þ¿É¼ÓËÙ²¡¶¾µÄÖ²¡Àú³Ì £¬»ùÓÚ´ËÑо¿ÕßÓÃHIV»ùÒòÖоßÓÐת¼»îÐÔµÄLTRÖÆ±¸×ª»ùÒòСÊó £¬HIV-1LTRÓ뱨¸æ»ùÒò´ó³¦°£Ï£¾úÂÈÃ¹ËØõ£»ù×ªÒÆÃ¸(chloramphenicol transferase,CAT)ijÈË¿¹ÒÈÂѰ×ø»ùÒò(α-1 antitrypsin,α-1-AT)ÈںϺó½¨ÉèÁËת»ùÒòСÊó £¬¸ÃСÊóÑÛ×éÖ¯ÖÐCAT±í´ïÉý¸ß5±¶ £¬ÑªÇåÖÐα-1-AT±í´ïÉϵ÷10~20±¶¡£ÔÚÍâ½çÒòËØ×÷ÓÃÏ £¬ Èç×ÏÍâÏßÕÕÉäºó £¬Æ¤·ô×éÖ¯ÖÐCAT¿ÉÉϵ÷30±¶ÒÔÉÏ¡£±í´ïHIV-1 LTR TatµÄת»ùÒòСÊó¿ÉÔÚÆ¤·ô×éÖ¯Öмì²âµ½LTR Tat RNAµÄ±í´ï £¬ÇÒÔÚ×ÏÍâÏßB»òC×÷ÓÃÏ £¬Æ¤·ôLTR Tat RNA±í´ïˮƽ¿É´ï10±¶ÒÔÉÏ¡£HIV-1ѬȾºó¿ÉÒýÆðÉñ¾­ÏµÍ³²¡±ä £¬Èç³Õ´ô×ÛºÏÕ÷µÈ(AIDS dementia complex) £¬ÇÒHIV-1²¡¶¾ÄÜ·ñÔÚÉñ¾­ÔªÏ¸°ûÖи´ÖÆÒ²²»ÇåÎú £¬HIV-1 LTR­LacZת»ùÒòСÊóÌåÄÚ¶à¸öÔàÆ÷¾ù¿É±í´ïLacZ RNA»òÂÑ°× £¬ÓÈÆäÊÇÄÔ¡¢ÊÓÍøÄ¤¼°ÖÐÊàÉñ¾­ÔªÏ¸°û¼ì²âµ½LacZ RNA±í´ï £¬ÕâЩЧ¹ûÅú×¢HIV-1¿ÉÔÚÉñ¾­ÔªÏ¸°û¸´ÖÆ¡£

3.HIVµ÷¿ØÂѰ×ת»ùÒòСÊó

¢ÅTat:TatÊÇHIV¸´ÖÆÀú³ÌÖÐÖ÷ÒªµÄµ÷¿ØÂÑ°× £¬¾ßÓÐת¼»îÐÔ £¬ÓÐÑо¿ÕßÒÔΪTat»îÐÔÓÐÒ»¶¨µÄÖÖÊôÌØÒìÐÔ £¬Æäת¼»îÐÔÖ»ÄÜÔÚÈËÔ´ÐÔϸ°ûÖоßÓÐ £¬¶øÔÚÊóÔ´ÐÔϸ°ûÖв»¾ß±¸´Ë¹¦Ð§¡£µ«±í´ïHIV-1 LTR TatµÄת»ùÒòСÊóÅú×¢Tat»îÐÔÎïÖÖÊôÌØÒìÐÔ £¬Ð¡Êó¿É±¬·¢Æ¤·ôËðÉ˵ÄÁÙ´²ÌåÏÖ £¬ÕâµãÓëAIDS»¼Õß¿¨²¨Î÷ÈâÁö¼«ÎªÏàËÆ £¬Æ¤·ô²¡±ä¼°ÔöÉúÔÚÐÛÐÔСÊóÖпÉά´ýÒ»ÄêÒÔÉÏ £¬Áè¼Ý18¸öÔµÄÐÛÐÔTatת»ùÒòÊó¸Î°©±¬·¢ÂÊ´óÓÚÆäËû¶¯Îï¡£

¢ÆNef:NefÂѰ×ÊÇÒ»ÖÖ¸ºµ÷¿ØÒò×Ó £¬Äܹ»ÔöÇ¿²¡¶¾µÄ¸´ÖÆÄÜÁ¦ºÍѬȾÐÔ¡£Nef»ùÒòÒÔÈËCD2Tϸ°ûÌØÒìÐÔµ÷¿ØÔª¼þ¼°ÆäLCRµ÷¿ØºóÖÆ±¸µÄת»ùÒòСÊó¿ÉÏÔ׎µµÍÍâÖÜѪCD4+Tϸ°ûÊýÄ¿¡£±ðµÄ £¬Nef»ùÒòÔÚÊóTϸ°ûÊÜÌåVβ8.3µÄβÁ´ÔöÇ¿×Ó/Æô¶¯×Ó¿ØÖÆÏÂÖÆ±¸µÄת»ùÒòÊóCD4+Tϸ°ûÊýĿϽµÏÔ×Å¡¢ÐØÏÙήËõ¡¢Æ¢¼°ÁÜͶºÏÖ×´ó £¬´ó¶¼¶¯ÎïÔÚ4~6¸öÔÂÄÚéæÃü¡£

4.±í´ïCD4¼°CCR5ºÍCXCR4ת»ùÒòСÊó CD4¼°CCR5ºÍCXCR4ÊÇHIV²¡¶¾ÊÜÌåºÍ¸¨ÖúÊÜÌå £¬Ç°ÒÑÐðÊöÓÉÓÚÈËCD4¡¢CCR5ºÍCXCR4ÓëСÊóµÄÕâЩ·Ö×ÓÐòÁвî±ð¿ÉÄܵ¼ÖÂСÊó¶ÔHIV-1²»Ãô¸Ð¡£±í´ïÈËCD4¼°Æä¸¨ÖúÊÜÌåCCR5µÄת»ùÒòСÊóÍâÖÜѪµ¥ºËϸ°û¼°Æ¢Ï¸°ûÖпɼì²âµ½¾ÞÊÉϸ°ûÊÈÐÔHIV¶¾Öê £¬Æ¢¼°ÁÜͶºÏ¾ù¿É¼ì²âµ½HIVDNA £¬µ«²¡¶¾²»¿ÉÔÚÕâЩ×éÖ¯ÖÐÔöÖ³¡£±í´ïÈËCD4¼°CXCR4ת»ùÒòСÊó¶ÔTϸ°ûÊÈÐÔHIV½ÏΪÃô¸Ð £¬ÍâÖÜѪÖÐCD4+Tϸ°ûÊýĿϽµÏÔ×Å¡£

¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º

Ä¿µÄ»ùÒòͨ¹ýÏÔ΢עÉä»òÆäËûת»ùÒòÒªÏòµ¼Èëµ½Êܾ«ÂÑϸ°ûºó £¬¿Éͨ¹ýPCR»òSouthern blotÒªÁì¼ì²âÄ¿µÄ»ùÒòÔÚ¶¯ÎïÌåÄÚ±í´ï¡£×ª»ùÒòСÊó³£ÓÃÓÚHIV·¢²¡»úÖÆÑо¿¡¢¿¹HIV-1Ò©Îïɸѡ¼°ÒßÃçѧÑо¿µÈ¡£

  

²Î¿¼ÎÄÏ×£º

1.Akkina R. New generation humanized mice for viru research: comparalive aspecls and future prospects Virology, 2013,435 (1):14-28

2.Boberg A, Bråve A,Johansson S,el al. Murine models for HIV vaccination and challenge. Expert Rev Vacci.nes, 2008, 7 (1):117-130

3.Hatziioannou T,Evans DT. Animal models for HIV/AIDS research. Nat Rev Microbiol,2012, 10 (12): 852-867

4.Hu SL. Non-human primate models for AIDS vaccine research. Curr Drug Targets Infect Disord,2005,5 (2):193-201

5.Nischang M, Gers-Huber G, Audig é A, el al. Modeling HIV infection and therapies in humanized mice. Swis Med Wkly,2012,142:wl3618

6.van Maanen M,Sutton RE. Rodent models for HIV-1 infection and disease. Curr HlV Res, 2003, 1(1):121- 130

7.Zhang L,Su L. HTV-1 immunopathogenesis in humanized mouse models. Cell Mol Immunol, 2012, 9 (3):237-244

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Ä£×ÓĿ¼
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > ÄÚÉøÍ¸¼°´úлÐÔ¼²²¡Ä£×Ó > ת»ùÒòСÊó°¬×̲¡¶¯ÎïÄ£×Ó
ת»ùÒòСÊó°¬×̲¡¶¯ÎïÄ£×Ó

ǰÑÔ

°¬×̲¡(acquired immunodeficiency syndrome,AIDS)ÔÚ1981ÄêÊ״η¢Ã÷ÓÚÃÀ¹ú £¬ËæºóÈ·¶¨Æä²¡Ô­ÌåΪÈËÀàÃâÒßȱÏݲ¡¶¾(human immunodeficiency virus,HIV),HIVÕ¹ÓÚ·´×ªÂ¼²¡¶¾Êô³ÉÔ± £¬ÊÇÒ»ÖÖѬȾÈËÀàÃâÒßϵͳϸ°ûµÄÂý²¡¶¾¡£²¡¶¾»ùÒò×éÓÉÁ½ÌõÏàͬµÄÕýÁ´RNA×é³É £¬È«³¤9.8kb £¬»®·Ö±àÂëGag¡¢Pol,Env½á¹¹ÂѰ׼°Tat¡¢Rev¡¢Vpu¡¢Vpr¡¢Vif¡¢NefµÈ¸¨ÖúÂѰס£HIVÓÐÁ½ÖÖѪÇåÐÍ £¬»®·ÖÊÇHIV-1ºÍHTV-2 £¬×î³£¼ûµÄΪHIV-1ѬȾ¡£HIVÈö²¥Í¾¾¶Ö÷Òª°üÀ¨ÐÔÈö²¥¡¢ÑªÒºÈö²¥ºÍĸӤÈö²¥µÈ;¾¶¾ÙÐÐÈö²¥ £¬Ñ¬È¾ºóÖ÷ÒªÇÖÕ¼ÃâÒßϸ°û £¬°üÀ¨Tϸ°û¡¢µ¥ºË¾ÞÊÉϸ°û¡¢Ê÷ͻ״ϸ°ûµÈ¡£Ï¸°ûÍâò±í´ïµÄCD4·Ö×ÓÊÇHIVÊÜÌå £¬HIVÄÒĤÌÇÂѰ×gp120Óëϸ°ûĤÉÏCD4·Ö×ÓÍŽáºó¿Éµ¼ÖÂѬȾµÄ±¬·¢ £¬AIDS»¼ÕßÁÙ´²ÌåÏÖÒÔCD4+TÁܰÍϸ°û¾ÙÐÐÐÔïÔÌ­ºÍÃâÒßȱÏÝÎªÌØÕ÷ £¬³£°éÓÐʵÖÊÆ÷¹Ù£¨ÄÔ¡¢ÁÜͶºÏºÍ·ÎµÈ£©µÄÑ×ÐÔ¼²²¡¡¢Éñ¾­Õϰ­ºÍ¶ñÐÔÖ×Áö¡£×ÔHIV±»·¢Ã÷ÒÔÀ´ £¬¿ÆÑ§¼ÒÃǼ´×îÏÈAIDS¶¯ÎïÄ£×ÓµÄÑо¿ÊÂÇé £¬Ð¡Êó¡¢Íü°·ÇÈËÁ鳤ÀදÎï¶¼ÔøÓÃÓÚAIDS¶¯ÎïÄ£×ÓµÄÑо¿¡£Æ¾Ö¤¶¯Îï¶ÔHIVµÄÃô¸ÐÐÔ¼°ÔìÄ£ÒªÁì £¬AIDS¶¯ÎïÄ£×Ó·ÖΪ·ÇÈËÁ鳤ÀදÎïÄ£×Ó¡¢×ª»ùÒòСÊóÄ£×Ó¼°ÈËÔ´»¯Ð¡ÊóÄ£×Ó¡£

·ÇÈËÁ鳤ÀදÎïÓÉÓÚËÇÑø±¾Ç®¸ß £¬ÇÒÐèÒªÌØÊâµÄËÇÑøÇéÐÎ £¬¸üÖ÷ÒªµÄÊÇÏÖÔÚÕë¶ÔÁ鳤ÀදÎïµÄÊÔ¼ÁºÜÉÙ £¬ÕâЩÒòËØ¶¼ÏÞÖÆÁËÆäÔÚ¶¯ÎïÄ£×ÓÑо¿ÖеÄÓ¦Óá£Ïà½ÏÁ¿¶øÑÔ £¬Äö³ÝÀදÎïÌåÐÍС¡¢Ò×ÓÚËÇÑø¡¢ÊÔ¼ÁȪԴÀû±ãµÈÒòËØ¾öÒéÁËÆäÔÚ¶¯ÎïÄ£×ÓÑо¿ÖÐÓÐÆæÒìµÄÓÅÊÆ¡£

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯ÎСÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

СÊó¶ÔHIV-1²¡¶¾²»Ò׸Р£¬HIV-1²¡¶¾²»¿ÉÔÚÆäÌåÄÚÔöÖ³¡£±¬·¢ÕâÖÖÕ÷ÏóµÄÔµ¹ÊÔ­ÓÉÒ»ÊÇСÊóºÍÈ˵ÄCD4·Ö×ÓÐòÁÐÓвî±ð £¬µ¼ÖÂHIV-1ÄÒĤÂѰײ»¿ÉÍŽᵽÊóCD4+Tϸ°û¡£Ò²ÓÐÑо¿·¢Ã÷HIV-1²¡¶¾ÐòÁÐÖг¤×îºóÖØ¸´ÐòÁÐ(long terminal repeat,LTR)½éµ¼µÄת¼»îÐÔÔÚÊóÔ´ÐÔϸ°û»îÐÔ½ÏµÍ £¬ÕâÒ²Êǵ¼ÖÂHIV-1²¡¶¾²»¿ÉѬȾСÊóµÄÔµ¹ÊÔ­ÓÉÖ®Ò»¡£±ðµÄ £¬HIV-1²¡¶¾µÄһЩ¸¨Öúµ÷¿ØÂÑ°× £¬Èç £¬ºËÊä³öÐźŷÖ×ÓRevÔÚÊóÔ´ÐÔϸ°ûÖеĹ¦Ð§Ï½µÏÔ×Å £¬²»¿ÉÓÐÓý鵼HIV-1mRNA³öºË £¬´Ó¶øÓ°Ï첡¶¾ÂѰ׷­ÒëºÍ°ü×°¡£Ëæ×Åת»ùÒòÊÖÒÕµÄÉú³¤ £¬½«HlV-1²¡¶¾ÊÜÌåCD4¼°Æä¸¨ÖúÊÜÌåCCR5ºÍCXCR4»ùÒòÈںϺóÏÔ΢עÉ䵽СÊóÊܾ«ÂÑϸ°û £¬ ¿ÉÖÆ±¸±í´ïÈËCD4-CCR5/CXCR4ת»ùÒòСÊó £¬¸ÃСÊóÓÉÓÚ±í´ïHIV-1²¡¶¾ÊÜÌå¼°¸¨ÖúÊÜÌå £¬Òò¶ø¶ÔHIV-1²¡¶¾µÄÒ׸ÐÐÔÌá¸ß £¬Ñ¬È¾ºó¿ÉÌåÏÖ³öAIDS²¿·ÖÖ¢×´¡£½«HIV-1²¡¶¾È«ÐòÁлò½á¹¹»ùÒò/µ÷¿Ø»ùÒò¿Ë¡ºóͨ¹ýÏÔ΢עÉäÒªÁìÒ²¿É½¨Éè±í´ïHIV-1ÌØÒìÂѰ׵Äת»ùÒòСÊó¡£

¡¾ÔìÄ£ÒªÁì¡¿£º

ͨ¹ýÏÔ΢עÉäÒªÁ콨ÉèµÄ±í´ïHIV-1²¡¶¾È«ÐòÁлò½á¹¹»ùÒò£¯µ÷¿Ø»ùÒòµÄת»ùÒòСÊó¿ÉÖ±½ÓÓÃÓÚ¿¹HIVÒ©Îïɸѡ¡¢ÒßÃçÆÀ¼ÛµÈÏà¹ØÑо¿ÁìÓò¡£300 TCID50µÄHIV-1²¡¶¾Æ¢ÄÚ½ÓÖÖ»ò8000TCID50HIV-1²¡¶¾¾²Âö½ÓÖÖCD4-CCR5ת»ùÒòСÊó £¬2~4Öܺó¶¯ÎïÔàÆ÷Öпɼì²âµ½HIV-1²¡¶¾DNA¡£

¡¾Ä£×ÓÌØµã¡¿£º

1.±í´ïHIV-1²¡¶¾ÐòÁÐת»ùÒòСÊó HIV-1ǰ²¡¶¾DNAÐòÁÐÏÔ΢עÉäµ½Êܾ«ÂÑϸ°ûºóÖÆ±¸³ö¿ÉÓÃÓÚAIDSÑо¿µÄת»ùÒòСÊó £¬×Ó´ú¶¯ÎïÖÐ50%~80£¥ÌåÏÖΪ±íƤÔöÉú¡¢ÁܰÍÑ×Ö¢¡¢Æ¢´ó¼°·ÎÁܰÍϸ°û½þÈóµÈ²¡ÀíÌåÏÖ £¬Æ¤·ô¡¢Æ¢Ô༰ÁÜͶºÏÖпɼì²âµ½HIV²¡¶¾¿ÅÁ£¡£Ò²ÓÐÑо¿ÕßÓÃȱʧGag-Pol»ùÒòµÄHIV-1²¡¶¾»ùÒòÐòÁÐÖÆ±¸AIDSת»ùÒòСÊóÄ£×Ó £¬¸ÃСÊóÉöÔàÖпɼì²âµ½HIV-1µÄÌØÒìÐÔ±í´ï £¬ºóÆÚСÊó¿ÉÉú³¤ÎªÓÐÂѰ×ÄòÖ¢×´µÄÉö²¡ÌåÏÖ £¬ÖÂËÀÂÊ½Ï¸ß £¬Òò´Ë¸ÃСÊóÓÃÓÚHIV-1ÒýÆðµÄÉö²¡Ä£×ÓÑо¿¡£±í´ï¸´ÖÆÈ±ÏÝÐÔHIV-1µÄת»ùÒòСÊóÒ²¿ÉÉú³¤ÓоÙÐÐÐÔÉöСÇòÓ²»¯ÎªÌåÏÖµÄÑÏÖØÉö²¡×ÛºÏÕ÷¡£±í´ïRevÂѰ׵Äת»ùÒòСÊóÉöСÇòÓ²»¯ £¬±íƤÔöÉú £¬Ð¡Ê󯤷ô×éÖ¯ÖÐÒ²¿É¼ì²âµ½²¡¶¾RNA¡£ÕâЩģ×ÓÊÇÑо¿HIVÏà¹ØÉö²¡µÄÓÅÒìÄ£×Ó¡£Ñо¿·¢Ã÷ÓÃMMTVÆô¶¯×ÓÈ¡´úHIVÆô¶¯×Óºó £¬EnvÂѰ׵Ägp160¡¢gp120ºÍGagÂѰ׵Äp55¡¢p24ÔÚת»ùÒòСÊóÌåÄÚ±í´ïÉϵ÷ £¬¸ÃÕ÷ÏóÓÈÆäÔÚ²¸ÈéÆÚ´ÆÐÔСÊóÖÐÌåÏÖÓÈÉõ¡£

2.HIV-1 LTRת»ùÒòСÊó »úÌåѬȾHIV-1ºóÓнϳ¤µÄDZÔÚÆÚ £¬ÁÙ´²Ö¢×´·ºÆð½ÏÍí £¬ÕâÓ벡¶¾×ªÂ¼»îÐÔÇ×½üÏà¹Ø¡£Ñо¿·¢Ã÷һЩÍâ½çÒòËØ£¨Èçϸ°ûÒò×Ó¡¢×ÏÍâÏߵȣ©¼°¾ßÓÐת¼»îÐԵĵ÷¿ØÔª¼þ¿É¼ÓËÙ²¡¶¾µÄÖ²¡Àú³Ì £¬»ùÓÚ´ËÑо¿ÕßÓÃHIV»ùÒòÖоßÓÐת¼»îÐÔµÄLTRÖÆ±¸×ª»ùÒòСÊó £¬HIV-1LTRÓ뱨¸æ»ùÒò´ó³¦°£Ï£¾úÂÈÃ¹ËØõ£»ù×ªÒÆÃ¸(chloramphenicol transferase,CAT)ijÈË¿¹ÒÈÂѰ×ø»ùÒò(α-1 antitrypsin,α-1-AT)ÈںϺó½¨ÉèÁËת»ùÒòСÊó £¬¸ÃСÊóÑÛ×éÖ¯ÖÐCAT±í´ïÉý¸ß5±¶ £¬ÑªÇåÖÐα-1-AT±í´ïÉϵ÷10~20±¶¡£ÔÚÍâ½çÒòËØ×÷ÓÃÏ £¬ Èç×ÏÍâÏßÕÕÉäºó £¬Æ¤·ô×éÖ¯ÖÐCAT¿ÉÉϵ÷30±¶ÒÔÉÏ¡£±í´ïHIV-1 LTR TatµÄת»ùÒòСÊó¿ÉÔÚÆ¤·ô×éÖ¯Öмì²âµ½LTR Tat RNAµÄ±í´ï £¬ÇÒÔÚ×ÏÍâÏßB»òC×÷ÓÃÏ £¬Æ¤·ôLTR Tat RNA±í´ïˮƽ¿É´ï10±¶ÒÔÉÏ¡£HIV-1ѬȾºó¿ÉÒýÆðÉñ¾­ÏµÍ³²¡±ä £¬Èç³Õ´ô×ÛºÏÕ÷µÈ(AIDS dementia complex) £¬ÇÒHIV-1²¡¶¾ÄÜ·ñÔÚÉñ¾­ÔªÏ¸°ûÖи´ÖÆÒ²²»ÇåÎú £¬HIV-1 LTR­LacZת»ùÒòСÊóÌåÄÚ¶à¸öÔàÆ÷¾ù¿É±í´ïLacZ RNA»òÂÑ°× £¬ÓÈÆäÊÇÄÔ¡¢ÊÓÍøÄ¤¼°ÖÐÊàÉñ¾­ÔªÏ¸°û¼ì²âµ½LacZ RNA±í´ï £¬ÕâЩЧ¹ûÅú×¢HIV-1¿ÉÔÚÉñ¾­ÔªÏ¸°û¸´ÖÆ¡£

3.HIVµ÷¿ØÂѰ×ת»ùÒòСÊó

¢ÅTat:TatÊÇHIV¸´ÖÆÀú³ÌÖÐÖ÷ÒªµÄµ÷¿ØÂÑ°× £¬¾ßÓÐת¼»îÐÔ £¬ÓÐÑо¿ÕßÒÔΪTat»îÐÔÓÐÒ»¶¨µÄÖÖÊôÌØÒìÐÔ £¬Æäת¼»îÐÔÖ»ÄÜÔÚÈËÔ´ÐÔϸ°ûÖоßÓÐ £¬¶øÔÚÊóÔ´ÐÔϸ°ûÖв»¾ß±¸´Ë¹¦Ð§¡£µ«±í´ïHIV-1 LTR TatµÄת»ùÒòСÊóÅú×¢Tat»îÐÔÎïÖÖÊôÌØÒìÐÔ £¬Ð¡Êó¿É±¬·¢Æ¤·ôËðÉ˵ÄÁÙ´²ÌåÏÖ £¬ÕâµãÓëAIDS»¼Õß¿¨²¨Î÷ÈâÁö¼«ÎªÏàËÆ £¬Æ¤·ô²¡±ä¼°ÔöÉúÔÚÐÛÐÔСÊóÖпÉά´ýÒ»ÄêÒÔÉÏ £¬Áè¼Ý18¸öÔµÄÐÛÐÔTatת»ùÒòÊó¸Î°©±¬·¢ÂÊ´óÓÚÆäËû¶¯Îï¡£

¢ÆNef:NefÂѰ×ÊÇÒ»ÖÖ¸ºµ÷¿ØÒò×Ó £¬Äܹ»ÔöÇ¿²¡¶¾µÄ¸´ÖÆÄÜÁ¦ºÍѬȾÐÔ¡£Nef»ùÒòÒÔÈËCD2Tϸ°ûÌØÒìÐÔµ÷¿ØÔª¼þ¼°ÆäLCRµ÷¿ØºóÖÆ±¸µÄת»ùÒòСÊó¿ÉÏÔ׎µµÍÍâÖÜѪCD4+Tϸ°ûÊýÄ¿¡£±ðµÄ £¬Nef»ùÒòÔÚÊóTϸ°ûÊÜÌåVβ8.3µÄβÁ´ÔöÇ¿×Ó/Æô¶¯×Ó¿ØÖÆÏÂÖÆ±¸µÄת»ùÒòÊóCD4+Tϸ°ûÊýĿϽµÏÔ×Å¡¢ÐØÏÙήËõ¡¢Æ¢¼°ÁÜͶºÏÖ×´ó £¬´ó¶¼¶¯ÎïÔÚ4~6¸öÔÂÄÚéæÃü¡£

4.±í´ïCD4¼°CCR5ºÍCXCR4ת»ùÒòСÊó CD4¼°CCR5ºÍCXCR4ÊÇHIV²¡¶¾ÊÜÌåºÍ¸¨ÖúÊÜÌå £¬Ç°ÒÑÐðÊöÓÉÓÚÈËCD4¡¢CCR5ºÍCXCR4ÓëСÊóµÄÕâЩ·Ö×ÓÐòÁвî±ð¿ÉÄܵ¼ÖÂСÊó¶ÔHIV-1²»Ãô¸Ð¡£±í´ïÈËCD4¼°Æä¸¨ÖúÊÜÌåCCR5µÄת»ùÒòСÊóÍâÖÜѪµ¥ºËϸ°û¼°Æ¢Ï¸°ûÖпɼì²âµ½¾ÞÊÉϸ°ûÊÈÐÔHIV¶¾Öê £¬Æ¢¼°ÁÜͶºÏ¾ù¿É¼ì²âµ½HIVDNA £¬µ«²¡¶¾²»¿ÉÔÚÕâЩ×éÖ¯ÖÐÔöÖ³¡£±í´ïÈËCD4¼°CXCR4ת»ùÒòСÊó¶ÔTϸ°ûÊÈÐÔHIV½ÏΪÃô¸Ð £¬ÍâÖÜѪÖÐCD4+Tϸ°ûÊýĿϽµÏÔ×Å¡£

¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º

Ä¿µÄ»ùÒòͨ¹ýÏÔ΢עÉä»òÆäËûת»ùÒòÒªÏòµ¼Èëµ½Êܾ«ÂÑϸ°ûºó £¬¿Éͨ¹ýPCR»òSouthern blotÒªÁì¼ì²âÄ¿µÄ»ùÒòÔÚ¶¯ÎïÌåÄÚ±í´ï¡£×ª»ùÒòСÊó³£ÓÃÓÚHIV·¢²¡»úÖÆÑо¿¡¢¿¹HIV-1Ò©Îïɸѡ¼°ÒßÃçѧÑо¿µÈ¡£

  

²Î¿¼ÎÄÏ×£º

1.Akkina R. New generation humanized mice for viru research: comparalive aspecls and future prospects Virology, 2013,435 (1):14-28

2.Boberg A, Bråve A,Johansson S,el al. Murine models for HIV vaccination and challenge. Expert Rev Vacci.nes, 2008, 7 (1):117-130

3.Hatziioannou T,Evans DT. Animal models for HIV/AIDS research. Nat Rev Microbiol,2012, 10 (12): 852-867

4.Hu SL. Non-human primate models for AIDS vaccine research. Curr Drug Targets Infect Disord,2005,5 (2):193-201

5.Nischang M, Gers-Huber G, Audig é A, el al. Modeling HIV infection and therapies in humanized mice. Swis Med Wkly,2012,142:wl3618

6.van Maanen M,Sutton RE. Rodent models for HIV-1 infection and disease. Curr HlV Res, 2003, 1(1):121- 130

7.Zhang L,Su L. HTV-1 immunopathogenesis in humanized mouse models. Cell Mol Immunol, 2012, 9 (3):237-244

¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿